Latest Conference Articles

Dr. Steven Grunberg, from the Vermont Cancer Center, Describes the 2012 Multinational Association of Supportive Care in Cancer Symposium.

Control of chemotherapy-induced nausea and vomiting (CINV) has come a long way in the past 30 years. Thirty years ago, about 10% of patients had complete control of emesis; in the 1990s about 50% had complete control. Today about 85% of patients treated with highly emetogenic chemotherapy have complete control of emesis.

Treatment of febrile neutropenia (FN) has dramatically improved over the past 3 decades, but there is room for improvement, according to Jean Klastersky, MD, Institut Jules Bordet, Brussels, Belgium.

Dr. Michael P. Link, ASCO President, from Stanford University School of Medicine, on the top stories from the 2012 ASCO Annual Meeting.

Photos taken at the 2012 ASCO Annual Meeting held at the McCormick Place in Chicago, Illinois, from June 1-5, 2012.

Dr. Marie Wood, from the University of Vermont, on Family Histories and Genetic Counseling for Breast and Colorectal Cancers.

The newer and more expensive breast cancer treatments nab-paclitaxel and ixabepilone, failed to demonstrate superior efficacy versus standard care with weekly paclitaxel.

The antidepressant duloxetine relieved pain associated with chemotherapy-induced peripheral neuropathy for 59% of patients.

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Drug manufacturers are working with the FDA to report anticipated shortages earlier and ensure alternative sources of needed drugs are available.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Trametinib and dabrafenib delayed disease progression and showed a trend toward improved survival in patients with advanced melanoma.

Dr. Caroline Robert, from the Institute Gustave Roussy in Paris, France, Discusses the MEK Inhibitor, Trametinib, METRIC Trial Results.

Dr. George Demetri, from Dana-Farber Cancer Institute, Discusses Regorafenib for Patients with GIST Trial Results.

The oral multikinase inhibitor regorafenib reduced the risk of disease progression by 73% in patients with gastrointestinal stromal tumors who had exhausted all other treatment options.

Afatinib markedly prolonged PFS compared with standard chemotherapy in patients with advanced lung adenocarcinomas that tested positive for EGFR mutations, particularly one of two common mutation types.

Bevacizumab plus chemotherapy as a second-line treatment for metastatic colorectal cancer improved survival among patients whose disease had progressed after first-line combination therapy with bevacizumab.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

Dr. Mathias Rummel, from University Hospital Giessen in Germany, on Bendamustine Plus Rituximab in Indolent and Mantle Cell Lymphomas

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

Bendamustine should become the preferred chemotherapy standard of care in initial combination regimens for indolent lymphomas and mantle cell lymphoma.

Patients with metastatic, hormone-sensitive prostate cancer and minimal disease spread experience a two-year boost in median survival when treated with continuous, rather than intermittent, hormonal therapy.

Dr. Eric Pujade-Lauraine, from Université de Paris Descartes, France, on the AURELIA Bevacizumab Trial for Platinum-Resistant Ovarian Cancer.

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Combining bevacizumab with standard chemotherapy reduced the risk of disease progression by 52% in patients with platinum-resistant ovarian cancer.

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Adolescent and young adult patients between the ages of 16 and 30 had poorer outcomes when given the same treatment regimen as younger acute lymphoblastic leukemia patients.

An immunotherapy agent that targets the PD-1 pathway demonstrated response rates as high as 28% in an early-phase study involving patients with different tumor types.

Dr. Michael Rotkowitz, from Cancer Treatment Centers of America, on Dabrafenib and Trametinib Combination Side Effects

Pharmaceutical industry analysts and companies have been weighing in on their selections for the most noteworthy research to be presented during the 2012 ASCO Annual Meeting.